The study consists of:
* a screening phase (maximum length of 7-day).
* a treatment phase with 21-day study treatment cycles. Patients continue to receive treatment until disease progression , death, unacceptable toxicity, investigator's decision or withdrawal of consent.
* a 30-day follow-up visit after the last dose of study medication.
